Medospir (Spironolactone)

Spironolactone blocks aldosterone receptors in the distal nephron of the kidney. This inhibition prevents sodium reabsorption and potassium excretion, leading to increased urinary sodium loss (diuresis) while retaining potassium, which helps lower blood pressure and reduce fluid buildup.

The appropriate dose of Medospir is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and laboratory results. Dosage adjustments are made to achieve therapeutic goals while minimizing adverse effects.

Safety data for spironolactone in pregnancy are limited, and the drug is generally avoided unless the potential benefit justifies the risk. It is excreted in breast milk, so breastfeeding mothers should consult their healthcare provider before using Medospir.

To request Medospir, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with loop diuretics, spironolactone offers a milder diuretic effect but uniquely spares potassium, reducing the risk of hypokalemia. It is often added to other diuretics for synergistic fluid control, especially when potassium conservation is desired.

Medospir should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in their original container, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Medospir is taken orally, usually with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

The most serious risks include severe hyperkalemia, which can cause cardiac arrhythmias, and acute kidney injury, especially when combined with other nephrotoxic agents. Prompt monitoring of serum potassium and renal function is essential.

Medospir is contraindicated in patients with known hypersensitivity to spironolactone, severe renal impairment, hyperkalemia, or those taking other potassium‑sparing medications without close monitoring. Clinicians should assess each patient’s medical history before prescribing.